OXiGENE is a biopharmaceutical company whose mission is finding and developing new and improved therapeutics that can deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions.
Wednesday, November 27, 2013
OXiGENE Appoints Frederick W. Driscoll to Its Board of Directors
Monday, November 18, 2013
OXiGENE Announces Preclinical Data Presentation on Novel Anticancer Compounds, Benzosuberenes, Demonstrating Potent Anti-Proliferative Activity